binge eating semaglutide Experts express alarm that GLP-1 RAs may trigger or worsen disorders. But is there any role they might play in eating disorder? And how can clinicians protect patients from risk? Eating disorder experts are worried

Christopher McGowan, the founder, medical director and research director of True You Weight Loss, a weight loss clinic in Cary, North Carolina

Monitoring: Cardiovascular: Heart rate (at regular intervals during Wegovy therapy) Gastrointestinal: For signs/symptoms of acute pancreatitis (after starting this drug) Metabolic: Blood glucose in patients with diabetes mellitus (before starting and during Wegovy therapy) Ocular: For progression of diabetic retinopathy in patients with history of diabetic retinopathy Renal: Renal function in patients with adverse reactions that could lead to volume depletion (during therapy, especially during initiation and escalation) Patient advice: Read the US FDA-approved patient labeling (Medication Guide and Instructions for Use, as applicable)

Unlimited Support: Ongoing guidance and answers to your questions, ensuring you never feel alone in your journey

Among the 45 gastrointestinal AEs, 17 new and unexpected AEs, including dry mouth, hypophagia, gastrointestinal sounds abnormal, bowel movement irregularity, feces discolored, pancreatic carcinoma metastatic, etc, were detected in our pharmacovigilance study, which were not reported in the drug label

This depends on a few factors